Texas A&M, along with the state of Texas, GSK, and officials from the U.S. department of Heath and Human Services have been collaborating on the development of a national pandemic influenza vaccine facility in Bryan, Texas. The institution will work as a main center of the Texas A&M Biocorridor, the scientific hub dedicated to develop biotechnology in Texas.
The Pandemic Influenza Vaccine Facility is expected to be completed by the end of the next year, and it will include a 100,000-square-foot facility, along with the adjacent Viral-based Vaccine Facility, which together will comprise the new effort to bolster national capabilities for managing pandemics. Once the new complex launches, it will then be followed by a start-up and validation phases, which are planned for the beginning of 2017. The plan is for the facility to work as a bulk antigen producer, able to yield up to 50 million adjuvanted pandemic influenza vaccine doses within four months of a declared influenza pandemic and availability of acceptable virus seeds.
“This facility represents a huge step forward for the State of Texas, and an important milestone in the United States’ battle against both contagious diseases and the specter of international bioterrorism,” Governor Perry announced at a dedication ceremony. “Our state has long been home to innovative minds willing to attempt giant leaps to great achievement, and this will serve as another instance where Texans are willing to lead the way to a safer and more prosperous future.”
Sharp also added that “Texas A&M has a long and proud tradition of dedicated service to our nation,” and the Pandemic Influenza Vaccine Facility and the adjacent Viral-based Vaccine Facility is planned to be the basis of the Texas A&M Center for Innovation in Advanced Development and Manufacturing (CIADM). It will be one of three national centers for innovation and the only one within an academic institution supported by the U.S. Department of Health and Human Services.